RDRosemarie H. DeKruyff

Rosemarie H. DeKruyff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rosemarie H. DeKruyff has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Dale T. Umetsu

    Boston Children's Hospital, Harvard Medical School, Boston, Mass

    5 shared publications
  • Kari Christine Nadeau

    Stanford University School of Medicine, Palo Alto, USA

    3 shared publications
  • Wenming Zhang

    Department of Medicine Sean N. Parker Center for Allergy and Asthma Research Stanford University School of Medicine Stanford California USA

    3 shared publications
  • Gerald Berry

    Division of Immunology and Transplantation Biology, Department of Pediatrics, and2Department of Pathology, Stanford University, Stanford, California 94305, USA3Department of Pathology, New York University School of Medicine, New York, New York 10016, USA

    2 shared publications
  • Gesine Hansen

    Division of Immunology, Department of Pediatrics, Stanford University, Stanford, California 94305, USA

    2 shared publications
  • Manisha Desai

    Department of Biomedical Data Science Stanford University Stanford California USA

    2 shared publications

Latest Publications

  • Open Access

    Cytometric analysis reveals an association between allergen-responsive natural killer cells and human peanut allergy

    by Xiaoying Zhou, Wong Yu, Diane M. Dunham, Jackson P. Schuetz, Catherine A. Blish, Rosemarie H. DeKruyff, Kari C. Nadeau

    Food allergies are a leading cause of anaphylaxis, and allergen-specific immune responses in both the innate and the adaptive immune system play key roles in its pathogenesis. We conducted a comprehensive phenotypic and functional investigation of immune cell responses from nonallergic (NA) and peanut allergic (PA) participants cultured with media alone or peanut protein and found, surprisingly, that NK cell activation was strongly associated with the immune response to allergen in PA participants. Peanut-responsive NK cells manifested a distinct expression pattern in PA participants compared with NA participants. Allergen-activated NK cells expressed both Th2 and immune regulatory cytokines, hinting at a potential functional role in mediating and regulating the Th2 allergic response. Depletion of CD3+ T cells attenuated the response of NK cells to peanut-allergen stimulation, suggesting that peanut-responsive NK cells are T cell dependent. We also showed that oral immune therapy was associated with decreased NK responses to peanut allergen stimulation in vitro. These results demonstrate that NK cells are associated with the food-allergic immune response, and the magnitude of this mobilized cell population suggests that they play a functional role in allergic immunity.


  • Gastrointestinal γδ T cells reveal differentially expressed transcripts and enriched pathways during peanut oral immunotherapy

    by Wenming Zhang, Gopal Krishna Dhondalay, Taryn Audrey Liu, Abhinav Kaushik, Ramona Hoh, Shirley Kwok, Neeraja Kambham, Nielsen Q Fernandez‐Becker, Sandra Andorf, Manisha Desai, et al.


  • Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab

    by Monali Manohar, Diane Dunham, Sheena Gupta, Zheng Yan, Wenming Zhang, Samantha Minnicozzi, Matthew Kirkey, Bryan Bunning, Roshni Roy Chowdhury, Stephen J. Galli, et al.

    Background: Multifood oral immunotherapy (mOIT) with adjunctive anti‐IgE (omalizumab, XOLAIR®) treatment affords safe, effective, and rapid desensitization to multiple foods, although the specific immune mechanisms mediating this desensitization remain to be fully elucidated.Methods: Participants in our phase 2 mOIT trial (NCT02643862) received omalizumab from baseline to week 16 and mOIT from week 8 to week 36. We compared the immune profile of PBMCs and plasma taken at baseline, week 8, and week 36 using high‐dimensional mass cytometry, component‐resolved diagnostics, the indirect basophil activation test, and Luminex.Results: We found (i) decreased frequency of IL‐4+ peanut‐reactive CD4+ T cells and a marked downregulation of GPR15 expression and CXCR3 frequency among γδ and CD8+ T‐cell subsets at week 8 during the initial, omalizumab‐alone induction phase; (ii) significant upregulation of the skin‐homing receptor CCR4 in peanut‐reactive CD4+ T and Th2 effector memory (EM) cells and of cutaneous lymphocyte‐associated antigen (CLA) in peanut‐reactive CD8+ T and CD8+ EM cells; (iii) downregulation of CD86 expression among antigen‐presenting cell subsets; and (iv) reduction in pro‐inflammatory cytokines, notably IL‐17, at week 36 post‐OIT. We also observed significant attenuation of the Th2 phenotype post‐OIT, defined by downregulation of IL‐4 peanut‐reactive T cells and OX40 in Th2EM cells, increased allergen component‐specific IgG4/IgE ratio, and decreased allergen‐driven activation of indirectly sensitized basophils.Conclusions: This exploratory study provides novel comprehensive insight into the immune underpinnings of desensitization through omalizumab‐facilitated mOIT. Moreover, this study provides encouraging results to support the complex immune changes that can be induced by OIT.


  • Open Access

    Blockade of RGMb inhibits allergen-induced airways disease

    by Sanhong Yu, Krystle M. Leung, Hye-Young Kim, Sarah E. Umetsu, Yanping Xiao, Lee A. Albacker, Hyun-Jun Lee, Dale T. Umetsu, Gordon J. Freeman, Rosemarie H. DeKruyff


  • Open Access

    Innate lymphoid cells in asthma: Will they take your breath away?

    by Hye Young Kim, Dale T. Umetsu, Rosemarie H. Dekruyff

    Asthma is a complex and heterogeneous disease that is characterized by airway hyper‐reactivity (AHR) and airway inflammation. Although asthma was long thought to be driven by allergen‐reactive TH2 cells, it has recently become clear that the pathogenesis of asthma is more complicated and associated with multiple pathways and cell types. A very exciting recent development was the discovery of innate lymphoid cells (ILCs) as key players in the pathogenesis of asthma. ILCs do not express antigen receptors but react promptly to “danger signals” from inflamed tissue and produce an array of cytokines that direct the ensuing immune response. The roles of ILCs may differ in distinct asthma phenotypes. ILC2s may be critical for initiation of adaptive immune responses in inhaled allergen‐driven AHR, but may also function independently of adaptive immunity, mediating influenza‐induced AHR. ILC2s also contribute to resolution of lung inflammation through their production of amphiregulin. Obesity‐induced asthma is associated with expansion of IL‐17A‐producing ILC3s in the lungs. Furthermore, ILCs may also contribute to steroid‐resistant asthma. Although the precise roles of ILCs in different types of asthma are still under investigation, it is clear that inhibition of ILC function represents a potential target that could provide novel treatments for asthma.


  • Open Access

    CD4+ T helper cells engineered to produce latent TGF-β1 reverse allergen-induced airway hyperreactivity and inflammation

    by Gesine Hansen, Jennifer J. McIntire, V. Peter Yeung, Gerald Berry, G. Jeanette Thorbecke, Lizhen Chen, Rosemarie H. DeKruyff, Dale T. Umetsu

    T helper 2 (Th2) cells play a critical role in the pathogenesis of asthma, but the precise immunological mechanisms that inhibit Th2 cell function in vivo are not well understood. Using gene therapy, we demonstrated that ovalbumin-specific (OVA-specific) Th cells engineered to express latent TGF-β abolished airway hyperreactivity and airway inflammation induced by OVA-specific Th2 effector cells in SCID and BALB/c mice. These effects correlated with increased concentrations of active TGF-β in the bronchoalveolar lavage (BAL) fluid, demonstrating that latent TGF-β was activated in the inflammatory environment. In contrast, OVA-specific Th1 cells failed to inhibit airway hyperreactivity and inflammation in this system. The inhibitory effect of TGF-β–secreting Th cells was antigen-specific and was reversed by neutralization of TGF-β. Our results demonstrate that T cells secreting TGF-β in the respiratory mucosa can indeed regulate Th2-induced airway hyperreactivity and inflammation and suggest that TGF-β–producing T cells play an important regulatory role in asthma.


  • Allergen-specific Th1 cells fail to counterbalance Th2 cell–induced airway hyperreactivity but cause severe airway inflammation

    by Gesine Hansen, Gerald Berry, Rosemarie H. DeKruyff, Dale T. Umetsu

    Allergic asthma, which is present in as many as 10% of individuals in industrialized nations, is characterized by chronic airway inflammation and hyperreactivity induced by allergen-specific Th2 cells secreting interleukin-4 (IL-4) and IL-5. Because Th1 cells antagonize Th2 cell functions, it has been proposed that immune deviation toward Th1 can protect against asthma and allergies. Using an adoptive transfer system, we assessed the roles of Th1, Th2, and Th0 cells in a mouse model of asthma and examined the capacity of Th1 cells to counterbalance the proasthmatic effects of Th2 cells. Th1, Th2, and Th0 lines were generated from ovalbumin (OVA)-specific T-cell receptor (TCR) transgenic mice and transferred into lymphocyte-deficient, OVA-treated severe combined immunodeficiency (SCID) mice. OVA-specific Th2 and Th0 cells induced significant airway hyperreactivity and inflammation. Surprisingly, Th1 cells did not attenuate Th2 cell–induced airway hyperreactivity and inflammation in either SCID mice or in OVA-immunized immunocompetent BALB/c mice, but rather caused severe airway inflammation. These results indicate that antigen-specific Th1 cells may not protect or prevent Th2-mediated allergic disease, but rather may cause acute lung pathology. These findings have significant implications with regard to current therapeutic goals in asthma and allergy and suggest that conversion of Th2-dominated allergic inflammatory responses into Th1-dominated responses may lead to further problems.


  • Differential regulation of antigen presentation in high‐ and low‐IgE responder mice

    by Luiz V. Rizzo, Dale T. Umetsu, Rosemarie H. Dekruyff

    Strains of mice differ greatly in their capacity to produce interleukin (IL) 4 and high levels of serum IgE. The contribution of macrophages (Mϕ) in enhancing the production of IL 4 by T cells in high‐IgE responder mice was studied. Mϕ from BALB/c mice (high‐IgE responder strain) developed an augmented capacity to present antigen to IL 4‐producing T helper type 2 (Th2) clones, when the Mϕ were pretreated by exposure to the lymphokines IL 4 and IL 5. In contrast, identical treatment of Mϕ from H‐2‐identical DBA/2 mice (low‐IgE responder strain) resulted in inhibition of the capacity to stimulate Th2 clones. The impairment of antigen presentation by DBA/2 Mϕ was closely paralleled by a decrease of cell surface class II major histocompatibility complex (MHC) expression and an abrogation of IL 1 production by these cells, while identical treatment of BALB/c Mϕ enhanced class II MHC expression and did not inhibit secretion of IL 1. Our studies demonstrate that IL 4 and IL 5 can exert different effects on Mϕ from high‐ and low‐IgE responder strains of mice, resulting in down‐regulation of the expansion of IL 4‐producing cells in low‐ but not high‐IgE responder mice.